Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mink Therapeutics Inc (NQ: INKT )

0.9619 -0.0281 (-2.84%)
Streaming Delayed Price Updated: 2:07 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mink Therapeutics Inc

< Previous 1 2 Next >
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Reports First Quarter 2024 Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
From MiNK Therapeutics
Via GlobeNewswire
MiNK Reports Fourth Quarter and Year-End 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model 
From MiNK Therapeutics
Via GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
Treatment with agenT-797 Showed Improved Survival in Severe Respiratory Distress 
From MiNK Therapeutics
Via GlobeNewswire
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
From MiNK Therapeutics
Via GlobeNewswire
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Second Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
From MiNK Therapeutics
Via GlobeNewswire
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference
From MiNK Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.